Perfluoroalkyl substances and beta cell deficient diabetes

Area of Science:

• Environmental Health
• Endocrinology
• Toxicology

Background:

• Perfluoroalkyl substances (PFAS) are synthetic chemicals with known effects on pancreatic islet cells, including preserving viability and reducing apoptosis.
• Previous research suggests a potential role for PFAS in metabolic health, but their association with diabetes, particularly different types, requires further investigation.

Purpose of the Study:

• To investigate the relationship between serum PFAS levels and the prevalence of diabetes.
• To determine if this association differs between type 1 diabetes, type 2 diabetes, and uncategorized diabetes.

Main Methods:

• Analysis of serum samples from 6,460 individuals with diabetes and 60,439 without diabetes from the C8 Health Project.
• Quantification of four specific PFAS: perfluorohexane sulfonate (PFHxS), perfluorooctanoic acid (PFOA), perfluorooctane sulfonate (PFOS), and perfluorononaoic acid (PFNA).
• Statistical analysis to assess the odds ratios (ORs) of diabetes in relation to PFAS levels, adjusting for age, sex, eGFR, and other covariates.

Main Results:

• Serum PFAS levels were significantly lower in individuals with diabetes compared to those without.
• The inverse association between PFAS and diabetes was most pronounced in type 1 diabetes.
• Adjusted analyses consistently showed lower odds of diabetes (all types) with higher serum PFAS concentrations, with ORs ranging from 0.59 to 0.95 across PFAS and diabetes types.

Conclusions:

• Serum PFAS levels are negatively associated with diabetes, suggesting a potential protective or indicative role.
• The stronger inverse relationship in type 1 diabetes may relate to the severity of pancreatic islet cell deficiency.
• Further research is warranted to elucidate the mechanisms underlying the observed inverse association between PFAS and diabetes.